RedHill Biopharma (RDHL) News Today $6.47 -0.38 (-5.55%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Moleculin Biotech (NASDAQ:MBRX) versus RedHill Biopharma (NASDAQ:RDHL) Head to Head ReviewNovember 21 at 2:18 AM | americanbankingnews.comRedHill Biopharma (NASDAQ:RDHL) Stock Price Passes Below Two Hundred Day Moving Average - Here's WhyNovember 20 at 3:51 AM | americanbankingnews.comRedHill Biopharma (NASDAQ:RDHL) Share Price Passes Below 200 Day Moving Average - Here's What HappenedNovember 12, 2024 | americanbankingnews.comRedHill Biopharma to Present Opaganib at U.S. Defense ConferenceOctober 29, 2024 | markets.businessinsider.comRedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRNDOctober 28, 2024 | prnewswire.comRedHill Biopharma and Duke Collaborate on Opaganib DevelopmentOctober 22, 2024 | markets.businessinsider.comRedHill Biopharma signs research pact with Duke University School of MedicineOctober 22, 2024 | markets.businessinsider.comRedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation InjuryOctober 22, 2024 | prnewswire.comRedHill: BARDA Selects Opaganib For Development & Funding As Medical Countermeasure To Treat EbolaOctober 14, 2024 | markets.businessinsider.comRedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola TreatmentOctober 14, 2024 | prnewswire.comRedHill Biopharma Secures Opaganib COVID-19 PatentOctober 1, 2024 | finance.yahoo.comRedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million CaliforniansOctober 1, 2024 | prnewswire.comRedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041September 30, 2024 | prnewswire.comRedHill Biopharma Ltd. (NASDAQ:RDHL) Sees Large Decline in Short InterestRedHill Biopharma Ltd. (NASDAQ:RDHL - Get Free Report) saw a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 49,800 shares, a drop of 58.7% from the August 31st total of 120,500 shares. Currently, 3.9% of the shares of the company are sold short. Based on an average daily volume of 317,400 shares, the days-to-cover ratio is presently 0.2 days.September 26, 2024 | marketbeat.comRedHill Biopharma (NASDAQ:RDHL) Stock Price Passes Below 200-Day Moving Average of $10.89RedHill Biopharma (NASDAQ:RDHL) Stock Price Crosses Below 200 Day Moving Average of $10.89September 12, 2024 | marketbeat.comRedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology GuidelinesSeptember 9, 2024 | prnewswire.comRedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 5, 2024 | prnewswire.comRedHill Biopharma (NASDAQ:RDHL) Stock Passes Below 200 Day Moving Average of $11.02RedHill Biopharma (NASDAQ:RDHL) Shares Cross Below 200-Day Moving Average of $11.02September 4, 2024 | marketbeat.comREDHILL B.AD 10000/IL-,01 (2RH.MU)September 3, 2024 | au.finance.yahoo.comNew Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 MortalitySeptember 3, 2024 | prnewswire.comRedHill Biopharma Ltd.: RedHill Biopharma Announces First Half 2024 Business HighlightsAugust 30, 2024 | finanznachrichten.deRedHill Biopharma Announces First Half 2024 Business HighlightsAugust 29, 2024 | prnewswire.comShort Interest in RedHill Biopharma Ltd. (NASDAQ:RDHL) Declines By 94.8%RedHill Biopharma Ltd. (NASDAQ:RDHL - Get Free Report) was the recipient of a large decline in short interest during the month of August. As of August 15th, there was short interest totalling 21,700 shares, a decline of 94.8% from the July 31st total of 417,400 shares. Based on an average daily trading volume, of 304,200 shares, the short-interest ratio is presently 0.1 days. Approximately 1.7% of the company's stock are short sold.August 27, 2024 | marketbeat.comRedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, NeuroblastomaAugust 26, 2024 | prnewswire.comRedHill Biopharma (NASDAQ:RDHL) Research Coverage Started at StockNews.comStockNews.com started coverage on RedHill Biopharma in a research note on Saturday. They issued a "hold" rating for the company.August 24, 2024 | marketbeat.comRedhill Biopharma Ltd (2RH0.SG)August 22, 2024 | nz.finance.yahoo.comTalicia® Launched in the United Arab EmiratesAugust 21, 2024 | prnewswire.comIsrael-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And DiabetesAugust 19, 2024 | msn.comRedHill Announces Positive Obesity and Diabetes Results with OpaganibAugust 19, 2024 | prnewswire.comRedHill Biopharma Ltd.: RedHill Biopharma Announces Plan to Implement ADS Ratio ChangeAugust 17, 2024 | finanznachrichten.deRedHill Biopharma Announces Plan to Implement ADS Ratio ChangeAugust 16, 2024 | prnewswire.comWhy Is RedHill Biopharma (RDHL) Stock Up 75% Today?August 1, 2024 | investorplace.comNewly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's DiseaseAugust 1, 2024 | prnewswire.comRaleigh pharma gets cash jolt at critical timeJuly 25, 2024 | bizjournals.comRedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® LienJuly 22, 2024 | prnewswire.comRedHill Biopharma Terminates License Agreement for Aemcolo®July 9, 2024 | prnewswire.comRedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040June 3, 2024 | prnewswire.comPensioners win £9,000 back in 16-year council tax battleMay 22, 2024 | uk.finance.yahoo.comRedHill Biopharma Ltd.: RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035May 7, 2024 | finanznachrichten.deRedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035May 6, 2024 | prnewswire.comRedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 StudyApril 24, 2024 | finance.yahoo.comRedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)April 10, 2024 | finance.yahoo.comRaleigh pharma weighs divesting commercial operationsApril 9, 2024 | bizjournals.comRedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2023 Results and Operational HighlightsApril 8, 2024 | finanznachrichten.deRedHill Biopharma Ltd. (2RH0.F)April 8, 2024 | finance.yahoo.comRedHill Biopharma Announces Full-Year 2023 Results and Operational HighlightsApril 8, 2024 | prnewswire.comRedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market PriceApril 2, 2024 | finance.yahoo.comRedHill Biopharma Receives New Patent For H. Pylori Treatment TaliciaMarch 11, 2024 | markets.businessinsider.comRedHill Announces New USPTO Patent Covering Talicia® Through 2034March 11, 2024 | finance.yahoo.comRedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures ProgramsMarch 5, 2024 | finance.yahoo.com Get RedHill Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin RDHL Media Mentions By Week RDHL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RDHL News Sentiment▼0.420.46▲Average Medical News Sentiment RDHL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RDHL Articles This Week▼21▲RDHL Articles Average Week Get RedHill Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MEI Pharma News Today OKYO Pharma News Today Citius Pharmaceuticals News Today Lexaria Bioscience News Today Elevation Oncology News Today Lantern Pharma News Today Surrozen News Today BioVie News Today ProMIS Neurosciences News Today ImmuCell News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RDHL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RedHill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share RedHill Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RDHL Stock Alerts